Health Technology Assessment
Scotland backs NHS use of Alexion’s Ultomiris for rare disease aHUS
Phil Taylor
Alexion, AstraZeneca, Health Technology Assessment, HEOR, nephrology, NHS, rare disease, Scotland, Soliris, Ultomiris
0 Comment
Market Access/ R&D/ Views & Analysis/ Views & Analysis/ Views and analysis
NICE talking to you: Trends in early HTA engagement
Deep Dive/ Market Access/ Views & Analysis/ Views and analysis
Improving access and reimbursement for specialty therapies
mike.hammerton@pharmaphorum.com
Deep Dive: Market Access, Health Technology Assessment, ICON, payers
0 Comment
NICE names Gillian Leng as CEO, replacing Andrew Dillon
Phil Taylor
Gillian Leng, Health Technology Assessment, NICE, senior management
0 Comment
MPs back Nebhrajani as NICE’s new chair after vetting meeting
Phil Taylor
appointment, Health Technology Assessment, NICE, senior management
0 Comment
NICE chair nominee Nebhrajani to face MP scrutiny next week
Phil Taylor
Health Technology Assessment, NICE, senior management
0 Comment
Market Access/ News/ News/ News/ News/ Patients/ Sales and Marketing/ Top stories
ICER methods could be illegal in US, claims US think tank
Phil Taylor
Health Technology Assessment, ICER, pricing, QALY, US, Value-based pricing
0 Comment
Market Access/ News/ News/ News/ Oncology
Scotland backs AZ’s Lynparza for first-line ovarian cancer maintenance
Phil Taylor
AstraZeneca, Health Technology Assessment, Lynparza, Merck & Co, Oncology, ovarian cancer, Scotland, Scottish Medicines Consortium
0 Comment